Common Contracts
2 similar Exclusive License Agreement contracts by Connect Biopharma Holdings LTD
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed AMENDMENT #3 TO EXCLUSIVE...Exclusive License Agreement • February 26th, 2021 • Connect Biopharma Holdings LTD • Pharmaceutical preparations
This Amendment #3 (this “Amendment”) is entered into as of November 19, 2020 (the “Amendment Effective Date”), by and between Arena Pharmaceuticals, Inc. (“Licensor”) and Connect Biopharm LLC (“Company”), and modifies the Exclusive License Agreement, dated June 19, 2012, by and between the parties, as amended (the “Existing Agreement”, and together with this Amendment, the “Agreement”).
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed AMENDMENT #3 TO EXCLUSIVE...Exclusive License Agreement • January 26th, 2021 • Connect Biopharma Holdings LTD • Pharmaceutical preparations
This Amendment #3 (this “Amendment”) is entered into as of November 19, 2020 (the “Amendment Effective Date”), by and between Arena Pharmaceuticals, Inc. (“Licensor”) and Connect Biopharm LLC (“Company”), and modifies the Exclusive License Agreement, dated June 19, 2012, by and between the parties, as amended (the “Existing Agreement”, and together with this Amendment, the “Agreement”).
